# Test Results: writing/specific-aims.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** writing/specific-aims.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am drafting a Specific Aims page for an NIH R21 (exploratory/developmental) on microbiome biomarkers for colorectal cancer screening. The funding agency emphasizes innovative approaches and high-risk/high-reward research.

My research plan notes:

Problem: Colorectal cancer is the 2nd leading cause of cancer death in the US. Colonoscopy screening is effective but has low compliance (~60%). Non-invasive biomarkers could improve screening rates. Current fecal tests (FIT, Cologuard) have limited sensitivity for adenomas.

My approach: Develop a microbiome-based classifier that detects precancerous adenomas from stool samples. Leverage the known microbiome changes in CRC to detect disease earlier.

Preliminary data:
- Pilot study with 25 adenoma cases, 25 controls
- 16S sequencing identified 12 differentially abundant taxa
- Random forest classifier achieved 78% AUC (needs validation)

Aim 1: Validate and refine the microbiome classifier in an independent cohort
- Partner with GI clinic for prospective sample collection
- Target 100 adenoma cases, 100 controls
- Test classifier performance and refine features

Aim 2: Integrate microbiome data with existing biomarkers (FIT)
- Hypothesis: combined model outperforms either alone
- Collect FIT results alongside microbiome samples
- Build integrated classifier

Innovation: First study to combine microbiome signatures with established screening biomarkers for adenoma detection

My lab: expertise in microbiome bioinformatics, machine learning, established GI collaborations

Target length: 1 page (R21 limit)

Task: Draft a Specific Aims page with the following structure:

**Opening paragraph (The Hook):**
- First sentence: Establish the problem and its significance (the "so what")
- Knowledge gap: What critical barrier limits progress?
- Your solution: How does your approach address this gap?
- Long-term goal and overall objective for this proposal

**Specific Aims (2-3 typically):**
For each aim:
- State the aim as a clear objective (what you will do)
- Brief rationale (why this aim matters)
- Approach summary (1-2 sentences on how)
- Expected outcome (what you'll learn)

**Closing paragraph:**
- How the aims integrate and build on each other
- Impact statement: what will be possible after this work that isn't possible now?
- Connection to agency mission (if applicable)

Constraints:
- Use ONLY information from my notes—do not fabricate preliminary data, citations, or capabilities
- Flag any claims that need preliminary data support as [NEEDS PRELIM DATA]
- Flag any citations needed as [CITE]
- Keep within target length
- Use active, confident language—avoid excessive hedging
- Make aims concrete and achievable within the funding period

Output format: Formatted aims page with section headers. Flag gaps for my attention.
````

## Model Output
````
# Specific Aims

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, yet it is largely preventable through early detection of precancerous adenomas [CITE: CRC incidence/mortality statistics]. Colonoscopy remains the gold standard for screening, but patient compliance is only ~60%, leaving millions at elevated risk [CITE: compliance rate source]. Non-invasive stool-based tests such as FIT and Cologuard have improved access to screening, but their sensitivity for detecting precancerous adenomas—the critical window for intervention—remains inadequate [CITE: FIT/Cologuard sensitivity data for adenomas]. **A critical gap exists: no validated, non-invasive biomarker strategy reliably detects adenomas before malignant transformation.** The gut microbiome is emerging as a promising source of disease-relevant biomarkers, as microbial community composition shifts measurably during CRC development [CITE: foundational microbiome-CRC studies], yet microbiome-based classifiers have not been integrated with established screening biomarkers to maximize detection performance. Our **long-term goal** is to develop a clinically deployable, non-invasive stool-based screening tool that improves early CRC detection and increases screening uptake. The **overall objective of this proposal** is to validate a microbiome-derived classifier for adenoma detection and determine whether integrating microbiome signatures with FIT results produces a superior combined diagnostic model. Our pilot data in 50 participants (25 adenoma cases, 25 controls) identified 12 differentially abundant taxa and yielded a random forest classifier with 78% AUC, providing the foundation for the studies proposed here.

---

## Aim 1: Validate and refine the stool microbiome classifier for adenoma detection in an independent prospective cohort.

**Rationale:** A classifier trained on 50 participants requires independent validation before clinical translation can be considered. Prospective collection in a real-world GI clinic setting will test generalizability and enable feature refinement under conditions that reflect intended use.

**Approach:** We will partner with our established GI clinic collaborators to prospectively collect stool samples and matched clinical data from 100 adenoma cases and 100 colonoscopy-confirmed controls. Samples will undergo 16S rRNA sequencing using our validated pipeline, and the existing random forest classifier will be tested in this independent cohort. We will apply regularization and feature selection methods to refine the taxon panel and optimize classifier performance.

**Expected Outcome:** A validated, refined microbiome classifier with defined sensitivity, specificity, and AUC in an independent cohort, and an optimized feature set suitable for integration in Aim 2.

> ⚑ **FLAG:** The 78% AUC from the pilot is promising but was achieved in a small, likely homogeneous sample. Consider adding a sentence acknowledging potential performance variation across demographic subgroups and whether your 100/100 cohort is powered to detect a meaningful AUC improvement. [NEEDS PRELIM DATA or power calculation to justify n=100 as sufficient for validation.]

---

## Aim 2: Determine whether integrating the microbiome classifier with FIT improves adenoma detection performance over either biomarker alone.

**Rationale:** FIT and microbiome signatures likely capture complementary biological signals—host mucosal bleeding and microbial dysbiosis, respectively. A combined model may achieve clinically meaningful sensitivity gains that neither biomarker achieves independently, addressing the core limitation of current non-invasive screening tools.

**Approach:** FIT results will be collected alongside microbiome samples from the Aim 1 cohort, enabling direct head-to-head and integrated analyses within the same participants. We will build a multivariate integrated classifier combining microbiome features and FIT scores, comparing performance of the combined model against each biomarker alone using cross-validated AUC, sensitivity, and specificity.

**Expected Outcome:** Quantitative evidence for whether microbiome-FIT integration provides additive diagnostic value, and a prototype integrated classifier with defined performance characteristics to support a future R01 validation trial.

> ⚑ **FLAG:** The innovation claim—"first study to combine microbiome signatures with established screening biomarkers for adenoma detection"—is strong but must be verified with a thorough literature search before submission. If prior studies exist, reframe as the first prospective, integrated classifier with head-to-head comparison. [CITE: confirm novelty or adjust claim.]

> ⚑ **FLAG:** You will need FIT data from the same participants as microbiome samples. Confirm your GI clinic protocol captures FIT results routinely or that your IRB/collection protocol explicitly includes FIT co-collection. Missing FIT data could undermine Aim 2.

---

## Closing

Aims 1 and 2 are deliberately sequential and synergistic: the validated, refined classifier from Aim 1 directly feeds the integration analysis in Aim 2, and both aims draw from the same prospective cohort, maximizing efficiency and internal consistency. Together, these aims will produce the first validated, integrated microbiome-FIT classifier for non-invasive adenoma detection—an advance that is not currently possible given the absence of independently validated microbiome classifiers in this space. **Successful completion will generate the performance data, biospecimen infrastructure, and analytical framework needed to support a fully powered R01 clinical validation trial.** This work aligns directly with NIH's priority to develop innovative, patient-centered approaches to cancer prevention and early detection, and with NCI's emphasis on reducing the burden of preventable cancer mortality through improved screening strategies [CITE: NCI strategic plan or relevant PA if applicable].

---

### ⚑ Summary of Flags for Your Attention

| # | Flag | Action Needed |
|---|------|---------------|
| 1 | CRC mortality/incidence statistic | Add citation (e.g., Siegel et al., CA Cancer J Clin) |
| 2 | 60% colonoscopy compliance rate | Add citation to source this figure |
| 3 | FIT/Cologuard adenoma sensitivity limitations | Add citation(s) to support this claim |
| 4 | Microbiome-CRC association | Add 2–3 foundational citations |
| 5 | Innovation claim ("first study") | Conduct literature search to confirm; adjust if needed |
| 6 | Power justification for n=100/100 | Add brief power calculation or rationale in Research Strategy |
| 7 | FIT co-collection logistics | Confirm IRB protocol and clinic workflow support this |
| 8 | NCI strategic plan alignment | Add specific PA number or NCI priority language if known |
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 (re-triage after max_tokens bump and re-capture). An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output is complete and ends cleanly with a flag-summary table. Follows the requested structure (opening hook → 2 aims with rationale/approach/expected outcome → closing). Uses `[CITE]` and `[NEEDS PRELIM DATA]` flags consistently rather than inventing references — meets the "use only information from my notes" constraint. Adds embedded `⚑ FLAG` callouts after each aim noting power calculation gaps, FIT co-collection logistics, and the innovation claim that needs literature verification. Two aims (within the 2-3 spec), aligned with the user's notes. The summary flag table at the end is helpful but may exceed strict R21 one-page formatting if rendered. No fabricated preliminary data — sticks to the n=50 pilot, 12 taxa, 78% AUC. NCI strategic plan reference is flagged `[CITE]` rather than fabricated. I cannot verify whether the prose actually fits within one R21 page when rendered, nor whether the flag callouts would be acceptable inline in a real submission.

**Suggested verdict (UNCONFIRMED):** Pass with notes

**What still needs human verification:**
- Whether the page-length target (1 page R21 limit) is actually met when rendered (the embedded flag callouts and summary table likely push it over)
- That the innovation claim ("first study to combine microbiome signatures with established screening biomarkers for adenoma detection") survives a real literature search
- The framing of Aim 2 as a "head-to-head and integrated" analysis aligns with the user's actual study capacity
- Whether n=100/100 is genuinely powered to detect a meaningful AUC improvement (flagged but not resolved)

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
